Download PDF
Tierarztl Prax Ausg K Kleintiere Heimtiere 2020; 48(06): 443-446
DOI: 10.1055/a-1295-2748
Kasuistik

Entwicklung einer großen intraprostatischen Zyste nach Einsatz eines GnRH-Agonist-Implantats bei einem Rüden mit benigner Prostatahyperplasie

Development of a large intraprostatic cyst following the use of a GnRH agonist-implant in a male dog with benign prostatic hyperplasia
Piotr Socha
Department für Reproduktion der Tiere, Ermländisch-Masurische Universität in Olsztyn, Polen
,
Tomasz Janowski
,
Slawomir Zduńczyk
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Ein Rüde mit benigner Prostatahyperplasie und mehreren kleineren intraprostatischen Zysten wurde mit einem GnRH-Agonist-Implantat mit 4,7 mg Deslorelin (Suprelorin®) behandelt. Innerhalb von 2 Wochen nach der Implantation kam es zur Verstärkung der zuvor aufgetretenen Blutung aus der Harnröhre. Sonografisch ließ sich eine große intraprostatische Zyste darstellen. Der Rüde wurde mit Osateronacetat (0,4 mg/kg p. o. 1-mal täglich über 7 Tage) und Enrofloxacin (5 mg/kg p. o. 1-mal täglich über 21 Tage) behandelt. Im Verlauf eines Monats bildete sich die Zyste vollständig zurück. Die Mechanismen der Zystenvergrößerung werden diskutiert.

Abstract

A male dog with benign prostatic hyperplasia and several small intraprostatic cysts was treated with a GnRH-agonist implant containing 4,7 mg deslorelin (Suprelorin®). Within 2 weeks after the implantation, the prior urethral bleeding worsened. A large intraprostatic cyst was detected sonographically. The patient was subsequently treated with osaterone acetate (0.4 mg/kg p. o. once a day for 7 days) and enrofloxacin (5 mg/kg p. o. once a day for 21 days). The clinical symptoms receded within 10 days. Within one month, the cyst regressed completely. The mechanisms of cyst enlargement are discussed.

Schlüsselwörter

Deslorelin - Nebenwirkung - Androgenrezeptorblocker - Osateronacetat

Key words

Deslorelin - side effect - androgen receptor inhibitor - osateronacetat


Publication History

Received: 30 July 2020

Accepted: 16 October 2020

Article published online:
04 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Berry SJ, Strandberg JD, Saunders WJ. et al. Development of canine benign prostatic hyperplasia with age. Prostate 1986; 9: 363-373
    CrossrefPubMedGoogle Scholar
  • 2 Black GM, Ling GV, Nyland TG. et al. Prevalence of prostatic cysts in adult, large-breed dogs. J Am Anim Hosp Assoc 1998; 34: 177-180
    CrossrefPubMedGoogle Scholar
  • 3 Brendler CB, Berry SJ, Ewing LL. et al. Spontaneous benign prostatic hyperplasia in the Beagle – Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. J Clin Invest 1983; 71: 1114-1123
    CrossrefPubMedGoogle Scholar
  • 4 Gloyna RE, Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. J Clin Invest 1970; 49: 1746-1753
    CrossrefPubMedGoogle Scholar
  • 5 Gobello C, Corrada Y. Noninfectious prostatic diseases in dogs. Compend Contin Educ Vet 2002; 24: 99-107
    PubMedGoogle Scholar
  • 6 Goericke-Pesch S, Hoffmann B. Benigne Prostatahyperplasie – Ätiologie, Klinik, Diagnostik und Therapie bei Rüden; eine Übersicht. Kleintierprax 2008; 53: 178-188
    PubMedGoogle Scholar
  • 7 Goericke-Pesch S, Wehrend A. GnRH-Agonisten in der Reproduktionsmedizin beim Kleintier – eine Übersicht. Tierärztl Prax 2009; 37 (K) 410-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Goericke-Pesch S, Wilhelm E, Ludwig C. et al. Evaluation of the clinical efficacy of Gonazon implants in the treatment of reproductive pathologies, behavioral problems, and suppression of reproductive function in the male dog. Theriogenology 2010; 73: 920-926
    CrossrefPubMedGoogle Scholar
  • 9 Hoffmann B, Goericke-Pesch S. Downregulated canine testis and recrudescence of testicular function following abolition of downregulation. Med Weter 2014; 70: 515-519
    PubMedGoogle Scholar
  • 10 Isaacs JT. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. J Steroid Biochem 1983; 18: 749-757
    CrossrefPubMedGoogle Scholar
  • 11 Johnston SD, Kamolpatana K, Root-Kustritz MV. et al. Prostatic disorders in the dog. Anim Reprod Sci 2000; 60–61: 405-415
    CrossrefPubMedGoogle Scholar
  • 12 Junaidi A, Williamson PE, Martin GB. et al. Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelin. Reprod Dom Anim 2009; 44: 725-734
    CrossrefPubMedGoogle Scholar
  • 13 Jurczak A, Domosławska A, Janowski T. et al. Treatment of benign prostatic hyperplasia (BPH) in dogs using GnRH agonist implant Suprelorin – preliminary results. Europ Vet Soc Small Anim Reprod 2010; 118
    PubMedGoogle Scholar
  • 14 Lowseth LA, Gerlach RF, Gillett NA. et al. Age related changes in the prostate and testes of the Beagle dog. Vet Pathol 1990; 27: 347-353
    CrossrefPubMedGoogle Scholar
  • 15 Ludwig C, Desmoulins PO, Driancourt MA. et al. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant “Gonazon”; a preclinical trial. Theriogenology 2009; 71: 1037-1045
    CrossrefPubMedGoogle Scholar
  • 16 Murakoshi M, Ikeda R, Tagawa M. et al. Immunolocalization of androgen receptor in canine prostatic hyperplasia – Effect of antiandrogen. Tokai J Exp Clin Med 1998; 23: 209-212
    PubMedGoogle Scholar
  • 17 Niżański W, Levy X, Ochota M. et al. Pharmacological treatment for common prostatic conditions in dogs – benign prostatic hyperplasia and prostatitis: an update. Reprod Dom Anim 2014; 49 (Suppl. 02) 8-15
    CrossrefPubMedGoogle Scholar
  • 18 Palm J, Reichler IM. Der Einsatz von Deslorelinazetat (Suprelorin) in der Kleintiermedizin. Schweiz Arch Tierheilk 2012; 154: 7-12
    CrossrefPubMedGoogle Scholar
  • 19 Parry NMA. The canine prostate gland: Part 1. Non-inflammatory diseases. UK Vet 2007; 12: 1-5
    PubMedGoogle Scholar
  • 20 Polisca A, Orlandi R, Troisi A. et al. Clinical efficacy of the GnRH agonist (Deslorelin) in dogs affected by benign prostatic hyperplasia and evaluation of prostatic blood flow by Doppler ultrasound. Reprod Domest Anim 2013; 48: 673-680
    CrossrefPubMedGoogle Scholar
  • 21 Renggli M, Padrutt I, Michel E. et al. Benigne Prostatahyperplasie: Therapiemöglichkeiten beim Hund. Schweiz Arch Tierheilk 2010; 152: 279-284
    CrossrefPubMedGoogle Scholar
  • 22 Riesenbeck A, Klein R, Hoffmann B. Downregulation, eine neue, reversible Möglichkeit zur Ausschaltung der Hodenfunktion beim Rüden. Prakt Tierarzt 2002; 83: 512-520
    Google Scholar
  • 23 Smith J. Canine prostatic disease: A review of anatomy, pathology, diagnosis, and treatment. Theriogenology 2008; 70: 375-383
    CrossrefPubMedGoogle Scholar
  • 24 Socha P, Zduńczyk S, Tobolski D. et al. Effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia. Polish J Vet Sci 2018; 21: 559-566
    PubMedGoogle Scholar
  • 25 Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol 2001; 3 (Suppl. 03) 10-14
    PubMedGoogle Scholar
  • 26 Trigg TE, Doyle AG, Walsh JD. et al. A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology 2006; 66: 1507-1512
    CrossrefPubMedGoogle Scholar
  • 27 Weaver AD. Discrete prostatic (paraprostatic) cysts in the dog. Vet Rec 1978; 20: 435-440
    CrossrefPubMedGoogle Scholar
  • 28 Weiss E. Männliche Geschlechtsorgane. In: Dahme E, Weiss E. Hrsg. Grundriss der speziellen pathologischen Anatomie der Haustiere. 6. Aufl.. Stuttgart: Enke; 2007: 203-213
    Google Scholar